Vedroprevir in the management of hepatitis C virus infection

References

• Hepatitis C. 2017 [Internet]. [cited 2017 Jul 21]. Available from: http://www.who.int/mediacentre/factsheets/fs164/en
   Google Scholar
• Guidelines for the screening, care, and treatment of persons with hepatitis C infection [Internet]. [cited 2017 Jul 21]. Available from: http://apps.who.int/iris/bitstream/10665/111747/1/9789241548755_eng.pdf?ua
   Google Scholar
• Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect. 2011 Feb;17(2):107–115.
   PubMed Web of Science ®Google Scholar
• Carney K, Dhalla S, Aytaman A, et al. Association of tattooing and hepatitis C virus infection: a multicenter case-control study. Hepatology. 2013 Jun;57(6):2117–2123.
   PubMed Web of Science ®Google Scholar
• Hoofnagle JH. Hepatitis C: the clinical spectrum of disease. Hepatology. 1997 Sep;26(3 Suppl 1):15S–20S.
   PubMed Web of Science ®Google Scholar
• George SL, Bacon BR, Brunt EM, et al. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. Hepatology. 2009 Mar;49(3):729–738.
   PubMed Web of Science ®Google Scholar
• Tachi Y, Hirai T, Miyata A, et al. Progressive fibrosis significantly correlates with hepatocellular carcinoma in patients with a sustained virological response. Hepatol Res. 2015 Jan;45(2):238–246.
   PubMed Web of Science ®Google Scholar
• D’Ambrosio R, Aghemo A, Rumi MG, et al. A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis. Hepatology. 2012 Aug;56(2):532–543.
   PubMed Web of Science ®Google Scholar
• Ismail MH. Prediction of sustained virologic responses to combination therapy of pegylated interferon-alpha and ribavirin in patients with chronic hepatitis C infection. J Family Community Med. 2013 Jan;20(1):35–40.
   PubMedGoogle Scholar
• Coppola N, Marrone A, Pisaturo M, et al. Role of interleukin 28-B in the spontaneous and treatment-related clearance of HCV infection in patients with chronic HBV/HCV dual infection. Eur J Clin Microbiol Infect Dis. 2014 Apr;33(4):559–567.
   PubMed Web of Science ®Google Scholar
• Gentile I, Viola C, Borgia F, et al. Telaprevir: a promising protease inhibitor for the treatment of hepatitis C virus infection. Curr Med Chem. 2009;16(9):1115–1121.
   PubMed Web of Science ®Google Scholar
• Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011 Mar 31;364(13):1195–1206.
   PubMed Web of Science ®Google Scholar
• Kohli A, Shaffer A, Sherman A, et al. Treatment of hepatitis C: a systematic review. JAMA. 2014 Aug 13;312(6):631–640.
   PubMed Web of Science ®Google Scholar
• Kohli A, Osinusi A, Sims Z, et al. Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study. Lancet. 2015 Mar 21;385(9973):1107–1113.
   PubMed Web of Science ®Google Scholar
• Osinusi A, Meissner EG, Lee YJ, et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA. 2013 Aug 28;310(8):804–811.
   PubMed Web of Science ®Google Scholar
• Osinusi A, Townsend K, Kohli A, et al. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. JAMA. 2015 Mar 24–31;313(12):1232–1239.
   PubMed Web of Science ®Google Scholar
• Kattakuzhy S, Levy R, Kottilil S. Sofosbuvir for treatment of chronic hepatitis C. Hepatol Int. 2015 Apr;9(2):161–173.
   PubMed Web of Science ®Google Scholar
• Sheng XC, Appleby T, Butler T, et al. Discovery of GS-9451: an acid inhibitor of the hepatitis C virus NS3/4A protease. Bioorg Med Chem Lett. 2012 Apr 1;22(7):2629–2634.
   PubMed Web of Science ®Google Scholar
• Yang H, Robinson M, Corsa AC, et al. Preclinical characterization of the novel hepatitis C virus NS3 protease inhibitor GS-9451. Antimicrob Agents Chemother. 2014;58(2):647–653.
   PubMed Web of Science ®Google Scholar
• Lawitz EJ, Hill JM, Marbury T, et al. A Phase I, randomized, placebo-controlled, 3-day, ascending-dose study of GS-9451, an NS3/4A protease inhibitor, in genotype 1 hepatitis C patients. Antivir Ther. 2013;18(3):311–319.
   PubMed Web of Science ®Google Scholar
• Lawitz E, Poordad F, Hyland RH, et al. Ledipasvir/sofosbuvir-based treatment of patients with chronic genotype-1 HCV infection and cirrhosis: results from two Phase II studies. Antivir Ther. 2016;21(8):679–687.
   PubMed Web of Science ®Google Scholar
• Lam BP, Jeffers T, Younoszai Z, et al. The changing landscape of hepatitis C virus therapy: focus on interferon-free treatment. Therap Adv Gastroenterol. 2015 Sep;8(5):298–312.
   PubMed Web of Science ®Google Scholar
• Kattakuzhy S, Wilson E, Sidharthan S, et al. Moderate sustained virologic response rates with 6-week combination directly acting anti-hepatitis C virus therapy in patients with advanced liver disease. Clin Infect Dis. 2016 Feb 15;62(4):440–447.
   PubMed Web of Science ®Google Scholar
• Kohli A, Kattakuzhy S, Sidharthan S, et al. Four-week direct-acting antiviral regimens in noncirrhotic patients with hepatitis C virus genotype 1 infection: an open-label, nonrandomized trial. Ann Intern Med. 2015 Dec 15;163(12):899–907.
   PubMed Web of Science ®Google Scholar
• Wilson EM, Kattakuzhy S, Sidharthan S, et al. Successful retreatment of chronic HCV genotype-1 infection with ledipasvir and sofosbuvir after initial short course therapy with direct-acting antiviral regimens. Clin Infect Dis. 2016 Feb 1;62(3):280–288.
   PubMed Web of Science ®Google Scholar
• Svarovskaia ES, Martin R, McHutchison JG, et al. Abundant drug-resistant NS3 mutants detected by deep sequencing in hepatitis C virus-infected patients undergoing NS3 protease inhibitor monotherapy. J Clin Microbiol. 2012 Oct;50(10):3267–3274.
   PubMed Web of Science ®Google Scholar
• Dvory-Sobol H, Wong KA, Ku KS, et al. Characterization of resistance to the protease inhibitor GS-9451 in hepatitis C virus-infected patients. Antimicrob Agents Chemother. 2012 Oct;56(10):5289–5295.
   PubMed Web of Science ®Google Scholar
• Trooskin SB, Reynolds H, Kostman JR. Access to costly new hepatitis C drugs: medicine, money, and advocacy. Clin Infect Dis. 2015 Dec 15;61(12):1825–1830.
   PubMed Web of Science ®Google Scholar
• Barua S, Greenwald R, Grebely J, et al. Restrictions for medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States. Ann Intern Med. 2015 Aug 4;163(3):215–223.
   PubMed Web of Science ®Google Scholar
• Liao JM, Fischer MA. Restrictions of hepatitis C treatment for substance-using medicaid patients: cost versus ethics. Am J Public Health. 2017 Jun;107(6):893–899.
   PubMed Web of Science ®Google Scholar
• Lo Re V 3rd, Gowda C, Urick PN, et al. Disparities in absolute denial of modern hepatitis C therapy by type of insurance. Clin Gastroenterol Hepatol. 2016 Jul;14(7):1035–1043.
   PubMed Web of Science ®Google Scholar